Faculty
Keith Stockerl-Goldstein.jpg

Keith E. Stockerl-Goldstein, MD

Associate Professor
Department of Medicine
Oncology Division
Bone Marrow Transplantation & Leukemia

Clinical Interests

  • Multiple myeloma / amyloidosis
  • Leukemia
  • Hodgkin's disease
  • Non-Hodgkin's lymphoma
  • Myelodysplastic syndrome
  • Stem cell transplantation

Contact

  • 314-454-8304 (tel)
  • 314-454-7551 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8007
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Peer-reviewed Articles

  • Results of Prospective Randomized, Open Label, Non-Inferiority Study of Tbo-Filgrastim (Granix(R)) Versus Filgrastim (Neupogen(R)) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
    Bhamidipati PK, Fiala MA, Grossman BJ, DiPersio JF, Stockerl-Goldstein K, Gao F, Uy GL, Westervelt P, Schroeder MA, Cashen AF, Abboud CN, Vij R
    Biol Blood Marrow Transplant 2017 Aug 7; [Epub ahead of print]
  • Allogeneic Transplantation for Advanced Acute Myeloid Leukemia: The Value of Complete Remission
    Weisdorf DJ, Millard HR, Horowitz MM, Hyare PS, Champlin R, Ho V, Mielcarek M, Rezvani A, Stockerl-Goldstein K, Khoury HJ, De Lima M, Saber W, Sandmaier B, Zhang MJ, Eapen M
    Cancer 2017 Jun 1;123(11):2025-2034
  • A Phase 1/2 Study of Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia
    Uy GL, Rettig MP, Stone RM, Konopleva MY, Andreeff M, McFarland K, Shannon W, Fletcher TR, Reineck T, Eades W, Stockerl-Goldstein K, Abboud CN, Jacoby MA, Westervelt P, DiPersio JF
    Blood Cancer J 2017 Mar 10;7(3):e542
  • Mobilization of Allogeneic Peripheral Blood Stem Cell Donors With Intravenous Plerixafor Mobilizes a Unique Graft
    Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, Mir FA, Shao J, McFarland K, Trinkaus K, Shannon W, Deych E, Yu J, Vij R, Stockerl-Goldstein K, Cashen AF, Uy GL, Abboud CN, Westervelt P, DiPersio JF
    Blood 2017 May 11;129(19):2680-2692
  • Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
    Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R
    J Natl Compr Canc Netw 2017 Feb;15(2):230-269
  • Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function After Allogeneic Hematopoietic Cell Transplantation
    Ghobadi A, Fiala MA, Ramsingh G, Gao F, Abboud CN, Stockerl-Goldstein K, Uy GL, Grossman BJ, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2017 Jul;23(7):1072-1077
  • The Impact of Diabetes Mellitus and Other Comorbidities on Hematopoietic Stem Cell Collection and Hematologic Recovery Post-Transplantation
    Fiala MA, Slade M, Wang S, Park S, DiPersio J, Stockerl-Goldstein K
    Leuk Lymphoma 2017 Jan;58(1):241-243
  • Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection
    Cashen AF, Rettig M, Gao F, Smith A, Abboud C, Stockerl-Goldstein K, Vij R, Uy G, Westervelt P, DiPersio J
    Biol Blood Marrow Transplant 2017 Aug;23(8):1282-1289
  • TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ
    N Engl J Med 2016 Nov 24;375(21):2023-2036
  • Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Stem Cell Transplant
    Motabi IH, Ghobadi A, Liu J, Schroeder M, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2016 Jul;22(7):1324-9
  • A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
    Wartman LD, Fiala MA, Fletcher T, Hawkins ER, Cashen A, DiPersio JF, Jacoby MA, Stockerl-Goldstein KE, Pusic I, Uy GL, Westervelt P, Vij R
    Leuk Lymphoma 2016 Mar;57(3):728-730
  • Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy
    Nedved AN, DeFrates SR, Hladnik LM, Stockerl-Goldstein KE
    Pharmacotherapy 2016 Oct;36(10):1087-1094
  • Phase I Study of Azacitidine Following Donor Lymphocyte Infusion for Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation
    Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG, Abboud C, Cashen A, Vij R, Schroeder MA, Pusic I, Stockerl-Goldstein K, Jacoby M, Uy G, DiPersio J, Westervelt P
    Leuk Res 2016 Oct;49:1-6
  • Remobilization of Hematopoietic Stem Cells in Healthy Donors for Allogeneic Transplantation
    Fiala MA, Park S, Slade M, DiPersio JF, Stockerl-Goldstein KE
    Transfusion 2016 Sep;56(9):2331-5
  • A Study of High-Dose Lenalidomide Induction and Low-Dose Lenalidomide Maintenance Therapy for Patients With Hypomethylating Agent Refractory Myelodysplastic Syndrome
    Cherian MA, Tibes R, Gao F, Fletcher T, Fiala M, Uy GL, Westervelt P, Jacoby MA, Cashen AF, Stockerl-Goldstein K, DiPersio JF, Vij R
    Leuk Lymphoma 2016 Nov;57(11):2535-2540
  • Phase II Study of Propylene Glycol-Free Melphalan Combined With Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
    Cashen AF, Fletcher T, Ceriotti C, Gao F, Ghobadi A, Vij R, Stockerl-Goldstein K, DiPersio J, Abboud C
    Biol Blood Marrow Transplant 2016 Dec;22(12):2155-2158
  • NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016
    Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R
    J Natl Compr Canc Netw 2016 Apr;14(4):389-400
  • Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience
    Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE
    J Clin Oncol 2015 Feb 1;33(4):340-8
  • High-Dose Therapy and Autologous Stem Cell Transplant in Older Adults With Multiple Myeloma
    Wildes TM, Finney JD, Fiala M, Gao F, Vij R, Stockerl-Goldstein K, Carson KR, Mikhael J, Colditz G
    Bone Marrow Transplant 2015 Aug;50(8):1075-82
  • Hematologic Recovery After Pretransplant Chemotherapy Does Not Influence Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
    Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R
    Biol Blood Marrow Transplant 2015 Aug;21(8):1425-30
  • Maintenance Therapy With Decitabine After Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
    Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2015 Oct;21(10):1761-9
  • Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Multiple Myeloma
    McBride A, Klaus JO, Stockerl-Goldstein K
    Am J Health Syst Pharm 2015 Mar 1;72(5):353-360
  • Bendamustine, Lenalidomide, and Dexamethasone (BRD) Is Highly Effective With Durable Responses in Relapsed Multiple Myeloma
    Kumar SK, Krishnan A, LaPlant B, Laumann K, Roy V, Zimmerman T, Gertz MA, Buadi FK, Stockerl-Goldstein K, Birgin A, Fiala M, Duarte L, Maharaj M, Levy J, Vij R
    Am J Hematol 2015 Dec;90(12):1106-10
  • A Phase I Study of Thymoglobulin for Relapsed or Refractory Multiple Myeloma
    Keller J, Fiala MA, Dipersio J, Stockerl-Goldstein K, Vij R, Heldermon CD
    Leuk Lymphoma 2015 Jun 19:1-3
  • A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
    Hari P, Aljitawi OS, Arce-Lara C, Nath R, Callander N, Bhat G, Allen LF, Stockerl-Goldstein K
    Biol Blood Marrow Transplant 2015 Dec;21(12):2100-2105
  • Retrospective Comparison of Allogeneic Vs Autologous Transplantation for Diffuse Large B-Cell Lymphoma With Early Relapse or Primary Induction Failure
    Ghobadi A, Nolley E, Liu J, McBride A, Stockerl-Goldstein K, Cashen A
    Bone Marrow Transplant 2015 Jan;50(1):134-136
  • Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma
    Fiala MA, Finney JD, Stockerl-Goldstein KE, Tomasson MH, DiPersio JF, Vij R, Wildes TM
    Biol Blood Marrow Transplant 2015 Jul;21(7):1153-4
  • Socioeconomic Status Is Independently Associated With Overall Survival in Patients With Multiple Myeloma
    Fiala MA, Finney JD, Liu J, Stockerl-Goldstein KE, Tomasson MH, Vij R, Wildes TM
    Leuk Lymphoma 2015 Sep;56(9):2643-9
  • Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
    Fadini GP, Fiala M, Cappellari R, Danna M, Park S, Poncina N, Menegazzo L, Albiero M, DiPersio J, Stockerl-Goldstein K, Avogaro A
    Diabetes 2015 Aug;64(8):2969-77
  • A Phase I Dose Escalation Study of Oral Bexarotene in Combination With Intravenous Decitabine in Patients With AML
    Welch JS, Niu H, Uy GL, Westervelt P, Abboud CN, Vij R, Stockerl-Goldstein KE, Jacoby M, Pusic I, Schroeder MA, DiPersio JF, Cashen AF
    Am J Hematol 2014 Aug;89(8):E103-8
  • A Phase II Study of V-BEAM as Conditioning Regimen Before Second Auto-SCT for Multiple Myeloma
    Wang TF, Fiala MA, Cashen AF, Uy GL, Abboud CN, Fletcher T, Wu N, Westervelt P, DiPersio JF, Stockerl-Goldstein KE, Vij R
    Bone Marrow Transplant 2014 Nov;49(11):1366-70
  • The Characteristics and Outcomes of Patients With Multiple Myeloma Dual Refractory or Intolerant to Bortezomib and Lenalidomide in the Era of Carfilzomib and Pomalidomide
    Wang TF, Ahluwalia R, Fiala MA, Trinkaus KM, Cox DP, Jaenicke M, Moliske CC, Carson KR, Wildes TM, Tomasson MH, Stockerl-Goldstein KE, Vij R
    Leuk Lymphoma 2014 Feb;55(2):337-41
  • Phase I Study of Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor (CLAG Regimen) and Midostaurin and All-Trans Retinoic Acid in Relapsed/Refractory AML
    Ramsingh G, Westervelt P, McBride A, Stockerl-Goldstein K, Vij R, Fiala M, Uy G, Cashen A, DiPersio JF, Abboud CN
    Int J Hematol 2014 Mar;99(3):272-8
  • Protective Effect of Cytomegalovirus Reactivation on Relapse After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen
    Manjappa S, Bhamidipati PK, Stockerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R
    Biol Blood Marrow Transplant 2014 Jan;20(1):46-52
  • Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia
    Jacoby MA, Martin MG, Uy GL, Westervelt P, DiPersio JF, Cashen A, Stockerl-Goldstein K, Vij R, Luo J, Reineck T, Bernabe N, Abboud CN
    Am J Hematol 2014 May;89(5):487-92
  • Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Elderly Patients With Newly Diagnosed Multiple Myeloma
    Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ
    Haematologica 2014 Sep;99(9):e162-4
  • Vorinostat Plus Tacrolimus and Mycophenolate to Prevent Graft-Versus-Host Disease After Related-Donor Reduced-Intensity Conditioning Allogeneic Haemopoietic Stem-Cell Transplantation: A Phase 1/2 Trial
    Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P
    Lancet Oncol 2014 Jan;15(1):87-95
  • Haploidentical Transplantation Using G-CSF-Mobilized T-Cell Replete PBSCs and Post-Transplantation CY After Non-Myeloablative Conditioning Is Safe and Is Associated With Favorable Outcomes
    Bhamidipati PK, DiPersio JF, Stockerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R
    Bone Marrow Transplant 2014 Aug;49(8):1124-6
  • A Phase 1 Study of Concomitant High-Dose Lenalidomide and 5-Azacitidine Induction in the Treatment of AML
    Ramsingh G, Westervelt P, Cashen AF, Uy GL, Stockerl-Goldstein K, Abboud CN, Bernabe N, Monahan R, DiPersio JF, Vij R
    Leukemia 2013 Mar;27(3):725-8
  • Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma
    Beason TS, Chang SH, Sanfilippo KM, Luo S, Colditz GA, Vij R, Tomasson MH, DiPersio JF, Stockerl-Goldstein K, Ganti A, Wildes T, Carson KR
    Oncologist 2013;18(10):1074-9
  • A Phase 1/2 Study of Chemosensitization With the CXCR4 Antagonist Plerixafor in Relapsed or Refractory Acute Myeloid Leukemia
    Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF
    Blood 2012 Apr 26;119(17):3917-24
  • Long-Term Outcome of Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells
    Muller AM, Kohrt HE, Cha S, Laport G, Klein J, Guardino AE, Johnston LJ, Stockerl-Goldstein KE, Hanania E, Juttner C, Blume KG, Negrin RS, Weissman IL, Shizuru JA
    Biol Blood Marrow Transplant 2012 Jan;18(1):125-33
  • A Phase 1/2 Study of Carfilzomib in Combination With Lenalidomide and Low-Dose Dexamethasone as a Frontline Treatment for Multiple Myeloma
    Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R
    Blood 2012 Aug 30;120(9):1801-9
  • Tandem Chemo-Mobilization Followed by High-Dose Melphalan and Carmustine With Single Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
    Chen AI, Negrin RS, McMillan A, Shizuru JA, Johnston LJ, Lowsky R, Miklos DB, Arai S, Weng WK, Laport GG, Stockerl-Goldstein K
    Bone Marrow Transplant 2012 Apr;47(4):516-21
  • Oral Valganciclovir Versus Ganciclovir as Delayed Pre-Emptive Therapy for Patients After Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Trial (04-0274) and Review of the Literature
    Chawla JS, Ghobadi A, Mosley J 3rd, Verkruyse L, Trinkaus K, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Westervelt P, DiPersio JF, Vij R
    Transpl Infect Dis 2012 Jun;14(3):259-67
  • Classifying Cytogenetics in Patients With Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study
    Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM, Artz AS, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten HC, Finke J, Ball ED, Aljurf MD, Cutler CS, Rowe JM, Antin JH, Isola LM, Di Bartolomeo P, Camitta BM, Miller AM, Cairo MS, Stockerl-Goldstein K, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes DW, Petersdorf EW, Devine SM, Maziarz RT, Bornhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer RJ, Weisdorf DJ
    Biol Blood Marrow Transplant 2012 Feb;18(2):280-8
  • Combination Decitabine, Arsenic Trioxide, and Ascorbic Acid for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Phase I Study
    Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, Cashen AF, Vij R
    Am J Hematol 2011 Sep;86(9):796-800
  • Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated With Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation
    Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, DiPersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA
    Biol Blood Marrow Transplant 2011 Nov;17(11):1646-52
  • A Phase 2 Study of High-Dose Lenalidomide as Initial Therapy for Older Patients With Acute Myeloid Leukemia
    Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Westervelt P, DiPersio JF, Vij R
    Blood 2011 Feb 10;117(6):1828-33
  • A Meta-Analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sezary Syndrome
    Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE
    Biol Blood Marrow Transplant 2009 Aug;15(8):982-90
  • Bortezomib Administered Pre-Auto-SCT and as Maintenance Therapy Post Transplant for Multiple Myeloma: A Single Institution Phase II Study
    Uy GL, Goyal SD, Fisher NM, Oza AY, Tomasson MH, Stockerl-Goldstein K, DiPersio JF, Vij R
    Bone Marrow Transplant 2009 May;43(10):793-800
  • A Phase II Study of 5-Day Intravenous Azacitidine in Patients With Myelodysplastic Syndromes
    Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, Westervelt P, Abboud CN, Kreisel F, Augustin K, DiPersio JF, Vij R
    Am J Hematol 2009 Sep;84(9):560-4
  • Allo-SCT Conditioning for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Clofarabine, Cytarabine and ATG
    Martin MG, Uy GL, Procknow E, Stockerl-Goldstein K, Cashen A, Westervelt P, Abboud CN, Augustin K, Luo J, DiPersio JF, Vij R
    Bone Marrow Transplant 2009 Jul;44(1):13-7
  • Salvage Therapy for Acute Myeloid Leukemia With Fludarabine, Cytarabine, and Idarubicin With or Without Gemtuzumab Ozogamicin and With Concurrent or Sequential G-CSF
    Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, DiPersio JF, Vij R
    Am J Hematol 2009 Nov;84(11):733-7
  • High-Dose Chemotherapy Followed by Stem Cell Rescue for High-Risk Germ Cell Tumors: The Stanford Experience
    Agarwal R, Dvorak CC, Stockerl-Goldstein KE, Johnston L, Srinivas S
    Bone Marrow Transplant 2009 Apr;43(7):547-52
  • Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation
    Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF
    Biol Blood Marrow Transplant 2008 Sep;14(9):1045-56
  • High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
    Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE
    Biol Blood Marrow Transplant 2006 Jul;12(7):703-11
  • Protective Conditioning for Acute Graft-Versus-Host Disease
    Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S
    N Engl J Med 2005 Sep 29;353(13):1321-31
  • Rapamycin (Sirolimus) for Treatment of Chronic Graft-Versus-Host Disease
    Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, Negrin RS, Chao NJ
    Biol Blood Marrow Transplant 2005 Jan;11(1):47-55
  • CD34, CD4, and CD8 Cell Doses Do Not Influence Engraftment, Graft-Versus-Host Disease, or Survival Following Myeloablative Human Leukocyte Antigen-Identical Peripheral Blood Allografting for Hematologic Malignancies
    Cao TM, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Negrin RS, Lowsky R
    Exp Hematol 2005 Mar;33(3):279-85
  • Engraftment and Survival Following Reduced-Intensity Allogeneic Peripheral Blood Hematopoietic Cell Transplantation Is Affected by CD8+ T-Cell Dose
    Cao TM, Shizuru JA, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Stuart MJ, Grumet FC, Negrin RS, Lowsky R
    Blood 2005 Mar 15;105(6):2300-6
  • A Randomized Trial of Amifostine and Carmustine-Containing Chemotherapy to Assess Lung-Protective Effects
    Jones RB, Stockerl-Goldstein KE, Klein J, Murphy J, Blume KG, Dansey R, Martinez C, Matthes S, Nieto Y
    Biol Blood Marrow Transplant 2004 Apr;10(4):276-82
  • Rituximab as Adjuvant to High-Dose Therapy and Autologous Hematopoietic Cell Transplantation for Aggressive Non-Hodgkin Lymphoma
    Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE, Johnston LJ, Wong RM, Shizuru JA, Horning SJ
    Blood 2004 Feb 1;103(3):777-83
  • Allografting With Nonmyeloablative Conditioning Following Cytoreductive Autografts for the Treatment of Patients With Multiple Myeloma
    Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, Storer B, Hegenbart U, Somlo G, Chauncey T, Bruno B, Appelbaum FR, Blume KG, Forman SJ, McSweeney P, Storb R
    Blood 2003 Nov 1;102(9):3447-54
  • Rapid Establishment of Dendritic Cell Chimerism in Allogeneic Hematopoietic Cell Transplant Recipients
    Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, Leong W, Grumet FC, Blume KG, Stockerl-Goldstein KE, Levy R, Shizuru JA
    Blood 2002 Feb 15;99(4):1442-8
  • Efficacy and Toxicity of a CCNU-Containing High-Dose Chemotherapy Regimen Followed by Autologous Hematopoietic Cell Transplantation in Relapsed or Refractory Hodgkin's Disease
    Stuart MJ, Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ, Shizuru JA, Long GD, Blume KG, Stockerl-Goldstein KE
    Biol Blood Marrow Transplant 2001;7(10):552-60
  • Rapid Engraftment After Allogeneic Transplantation of Density-Enriched Peripheral Blood CD34+ Cells in Patients With Advanced Hematologic Malignancies
    Cao TM, Kusnierz-Glaz C, Valone F, Stockerl-Goldstein KE, Hu WW, Johnston L, Blume KG, Strober S, Negrin RS
    Cancer 2001 Jun 15;91(12):2205-13
  • High-Dose Therapy and Autologous Hematopoietic-Cell Transplantation for Follicular Lymphoma Beyond First Remission: The Stanford University Experience
    Cao TM, Horning S, Negrin RS, Hu WW, Johnston LJ, Taylor TL, Shizuru JA, Hoppe RT, Brown BW, Blume KG, Stockerl-Goldstein KE
    Biol Blood Marrow Transplant 2001;7(5):294-301
  • Favorable Treatment Outcome in Non-Hodgkin's Lymphoma Patients With "Poor" Mobilization of Peripheral Blood Progenitor Cells
    Stockerl-Goldstein KE, Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW, Johnston LF, Long GD, Strober S, Wong RM, Feiner RH, Kobler S, Negrin RS
    Biol Blood Marrow Transplant 2000;6(5):506-12
  • Transplantation of Highly Purified CD34+Thy-1+ Hematopoietic Stem Cells in Patients With Metastatic Breast Cancer
    Negrin RS, Atkinson K, Leemhuis T, Hanania E, Juttner C, Tierney K, Hu WW, Johnston LJ, Shizurn JA, Stockerl-Goldstein KE, Blume KG, Weissman IL, Bower S, Baynes R, Dansey R, Karanes C, Peters W, Klein J
    Biol Blood Marrow Transplant 2000;6(3):262-71
  • Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Progenitor Cell Transplantation for Multiple Myeloma
    Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R
    Biol Blood Marrow Transplant 2000;6(6):621-7
  • Toxicity of High-Dose Sequential Chemotherapy and Purged Autologous Hematopoietic Cell Transplantation Precludes Its Use in Refractory/Recurrent Non-Hodgkin's Lymphoma
    Johnston LJ, Stockerl-Goldstein KE, Hu WW, Negrin RS, Hoppe RT, Blume KG, Horning SJ
    Biol Blood Marrow Transplant 2000;6(5A):555-62
  • Four-Cycle High-Dose Therapy With Hematopoietic Support for Metastatic Breast Cancer: No Improvement in Outcomes Compared With Single-Course High-Dose Therapy
    Hu WW, Negrin RS, Stockerl-Goldstein K, Johnston LJ, Shizuru JA, Wong RM, Chao NJ, Long GD, Feiner RH, Blume KG
    Biol Blood Marrow Transplant 2000;6(1):58-69
  • High-Dose Chemotherapy and Hematopoietic Stem Cell Rescue for Breast Cancer: Experience in California
    Damon LE, Hu WW, Stockerl-Goldstein KE, Blume KG, Wolf JL, Gold E, Cecchi GR, Irwin D, Glaspy J, Territo I, Miller W, Mason JR, Linker CA
    Biol Blood Marrow Transplant 2000;6(5):496-505
  • Effect of Oral Glutamine Supplementation During Bone Marrow Transplantation
    Coghlin Dickson TM, Wong RM, offrin RS, Shizuru JA, Johnston LJ, Hu WW, Blume KG, Stockerl-Goldstein KE
    JPEN J Parenter Enteral Nutr 2000 Mar-Apr;24(2):61-6
  • Equivalence of 2 Effective Graft-Versus-Host Disease Prophylaxis Regimens: Results of a Prospective Double-Blind Randomized Trial
    Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS, Long GD, Hu WW, Stockerl-Goldstein KE, Johnston LJ, Amylon MD, Tierney DK, O'Donnell MR, Nademanee AP, Parker P, Stein A, Molina A, Fung H, Kashyap A, Kohler S, Spielberger R, Krishnan A, Rodriguez R, Forman SJ, Bluzme KG
    Biol Blood Marrow Transplant 2000;6(3):254-61
  • Pulmonary Toxicity Syndrome in Breast Cancer Patients Undergoing BCNU-Containing High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation
    Cao TM, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor TL, Rizk NW, Wong RM, Blume KG, Hu WW
    Biol Blood Marrow Transplant 2000;6(4):387-94
  • High-Dose Therapy With Hematopoietic Cell Transplantation for Patients With Central Nervous System Involvement by Non-Hodgkin's Lymphoma
    Alvarnas JC, Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, Stockerl-Goldstein K, Tierney K, Wong R, Blume KG, Chao NJ
    Biol Blood Marrow Transplant 2000;6(3A):352-8
  • Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma--A Feasibility Study
    Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R
    Blood 1999 Apr 1;93(7):2411-9
  • A Feasibility Study of Multiple Cycle Therapy With Melphalan, Thiotepa, and Paclitaxel Followed by Mitoxantrone, Thiotepa, and Paclitaxel With Autologous Hematopoietic Cell Support for Metastatic Breast Cancer
    Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG
    Clin Cancer Res 1999 Nov;5(11):3411-8
  • Impact of Admission Body Weight and Chemotherapy Dose Adjustment on the Outcome of Autologous Bone Marrow Transplantation
    Dickson TM, Kusnierz-Glaz CR, Blume KG, Negrin RS, Hu WW, Shizuru JA, Johnston LL, Wong RM, Stockerl-Goldstein KE
    Biol Blood Marrow Transplant 1999;5(5):299-305
  • Rationale for Adjuvant Idiotypic Vaccination After High-Dose Therapy for Multiple Myeloma
    Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, Levy R
    Biol Blood Marrow Transplant 1997 Aug;3(3):157-63
  • Fractionated Total-Body Irradiation, Etoposide, and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With High-Risk or Advanced-Stage Hematological Malignancies
    Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG
    Biol Blood Marrow Transplant 1997 Dec;3(6):324-30
  • Influence of Preparatory Regimen and Source of Hematopoietic Cells on Outcome of Autotransplantation for Non-Hodgkin's Lymphoma
    Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD, Hoppe RT, Amylon MD, Brown BW Jr, Wong RM, Blume KG
    Biol Blood Marrow Transplant 1996 May;2(2):76-85